Almac Clinical Technologies

## Covariate Adaptive (Dynamic) Randomization

Presented to Gilead by Almac Biostats:

Kevin Venner, Lead Biostatistician

Jennifer Ross, Director of Biostatistics



INTERACTIVE RESPONSE TECHNOLOGY











## **CAR Methodologies**

#### ICH E9:

- "The use of a dynamic allocation procedure may help to <u>achieve balance across a number of</u> stratifying factors simultaneously provided the rest of the trial procedures can be adjusted to accommodate an approach of this type."
- "Dynamic allocation is an alternative procedure in which the <u>allocation of treatment to a subject is</u> <u>influenced by the current balance of allocated treatments</u> and, in a stratified trial, by the stratum to which the subject belongs and the balance within that stratum."

#### **Almac Biostats:**

- In other words, there is <u>no Stratified List</u> that will tell you the 1<sup>st</sup>, 2<sup>nd</sup>, 3<sup>rd</sup>,... treatment assignment.
- Treatment assignments will be made dynamically via an algorithm.





#### **CAR Considerations**

#### EMA: Points to Consider on Adjustment for Baselines Covariates (2003)

http://www.ema.europa.eu/docs/en\_GB/document\_library/Scientific\_guideline/2009/09/WC500003639.pdf:

- **I.3.** "...such methods remain highly controversial. Thus, applicants are strongly advised to avoid such methods. If they are used, the reasons should be justified on solid clinical and statistical grounds."
- II.4. "Dynamic allocation is strongly discouraged... Applicants will be required to describe the sensitivity analyses they intend to perform to support the conclusions from the primary analysis." Without adequate and supporting/sensitivity analyses, an application is unlikely to be successful."

#### To use CAR, the following 2 areas of justification is required:

#### 1. Clinical Justification:

- All stratification factors used are clinically justified
- Evidence / reasoning of why there could be statistical differences across the levels
   (e.g. science suggests that potential differences exist across the stratification factor levels because...)

#### 2. Statistical Justification:

- Given the number of Stratification Factors, Sample Size and Treatment Ratio;
- Treatment Balance can <u>only</u> be achieved through a dynamic allocation method VERSUS
- Standard list-based randomization method (where balance would be compromised).
- Simulations are often required to provide / prove Statistical Justification.



### CAR Considerations (continued)

#### EMA: Guideline on adjustment for baseline covariates in clinical trials (2015), Section 4.2:

http://www.ema.europa.eu/docs/en\_GB/document\_library/Scientific\_guideline/2015/03/WC500184923.pdf -

- "... The (simplified) idea behind dynamic allocation is to measure the imbalance marginally over each prognostic factor and to minimize e.g. the (weighted) sum of imbalances over all prognostic factors, thus maximising overall balance. However, dynamic allocation does not guarantee balance within combinations of prognostic factors.

  Deterministic schemes should be avoided."
- "Possible implications of dynamic allocation methods on the analysis e.g. with regard to bias and Type I error control should be carefully considered, taking into account that for some situations (e.g. planned unbalanced treatment allocation that allows to change the allocation ratio at every allocation) it has been shown that in case of dynamic treatment allocation conventional statistical methods do not always control the Type I error. To properly account for such problems the use of re-randomisation methods in the analysis should be considered."

#### **Key Points:**

- CAR balances within Factor Levels, but does not guarantee Stratum Level (cross-combination) balance
- Standard Blocked Randomization would balance within the cross-combination Stratum Levels
- CAR algorithm should have an appropriate Random Component (e.g. biased coin probability value < .90)</li>
- Biased coin probability value = 0.90 is akin to Block Size = 2 for Blocked Rand List; not recommended due to predictability
- If using CAR, you should be prepared to do re-randomization at the end of the study to prove Type I error did not occur
- Re-randomization typically not required for Standard Blocked Randomization

IXRS'3

#### Parameterization Notes

- Treatment Codes / Ratios
- Balance Factors & Levels (Stratification)
  - STUDY an optional factor that provides additional protection to maintaining Study level balance
    - May not be needed if other factors have low number of levels
  - SITE: Trending away from using SITE as a balancing factor
    - Standard of Care may be similar across SITEs within the same Country / Region
    - May not be feasible given Covid-19 climate (where Site transfers are common)
    - Consider using Region or Country (more clinically meaningful, stable, consistent across study duration)
- Factor Weights: can be applied to each factor according to the importance of obtaining treatment balance
- Treatment Assignment Probability (p)
  - Biased-coin probability value (common values = 0.70, 0.75, 0.80, 0.85)
  - In case of TIE, assign according to allocation ratio
  - General rule: select the lowest value that provides the required treatment balance (to avoid predictability)

## E Built to Adapt

### Minimization (Pocock & Simon, 1975) Algorithm Example

**Current Status: 49 Subjects enrolled (25xA, 24xB)** 

| Factor        | Level | Trt A | Trt B | Total |
|---------------|-------|-------|-------|-------|
| Site          | 1     | 5     | 5     | 10    |
|               | 2     | 11    | 10    | 21    |
|               | 3     | 9     | 9     | 18    |
| Gender        | M     | 13    | 11    | 24    |
|               | F     | 12    | 13    | 25    |
|               | 1     | 5     | 4     | 9     |
| Symptom Score | 2     | 13    | 15    | 28    |
|               | >=3   | 7     | 5     | 12    |
| Study         | All   | 25    | 24    | 49    |

New subject (50th) to be randomized into study: SITE=2, GENDER=M, SYMPTOMS SCORE=2

| Factor        | Level | Trt A | Trt B | Total |
|---------------|-------|-------|-------|-------|
|               | 1     | 5     | 5     | 10    |
| Site          | 2     | 11    | 10    | 21    |
|               | 3     | 9     | 9     | 18    |
| Gender        | M     | 13    | 11    | 24    |
|               | F     | 12    | 13    | 25    |
|               | 1     | 5     | 4     | 9     |
| Symptom Score | 2     | 13    | 15    | 28    |
|               | >=3   | 7     | 5     | 12    |
| Study         | All   | 25    | 24    | 49    |

# E. Built to Adapt

## Minimization Algorithm Example (Continued)

Step 1. Calculate imbalance assuming new subject is randomized to Trt A

| Factor        | Level | Trt A  | Trt B            | Diff            |
|---------------|-------|--------|------------------|-----------------|
|               | 1     | 5      | 5                |                 |
| Site          | 2     | 11 + 1 | 10               | Diff(12,10) = 2 |
|               | 3     | 9      | 9                |                 |
| Condor        | M     | 13 + 1 | 11               | Diff(14,11) = 3 |
| Gender        | F     | 12     | 13               |                 |
|               | 1     | 5      | 4                |                 |
| Symptom Score | 2     | 13 + 1 | 15               | Diff(14,15) = 1 |
|               | >=3   | 7      | 5                |                 |
| Study         | All   | 25 + 1 | 24               | Diff(26,24) = 2 |
|               |       | Т      | otal Imbalance A | 8               |

## E Built to Adapt

## Minimization Algorithm Example (Continued)

Step 2. Calculate imbalance assuming new subject is randomized to Trt B

| Factor        | Level | Trt A             | Trt B  | Diff            |
|---------------|-------|-------------------|--------|-----------------|
|               | 1     | 5                 | 5      |                 |
| Site          | 2     | 11                | 10 + 1 | Diff(11,11) = 0 |
|               | 3     | 9                 | 9      |                 |
| Condor        | M     | 13                | 11 + 1 | Diff(13,12) = 1 |
| Gender        | F     | 12                | 13     |                 |
|               | 1     | 5                 | 4      |                 |
| Symptom Score | 2     | 13                | 15 + 1 | Diff(13,16) = 3 |
|               | >=3   | 7                 | 5      |                 |
| Study         | All   | 25                | 24 + 1 | Diff(25,25) = 0 |
|               |       | Total Imbalance B |        | 4               |

Step 3. Determine which treatment will minimize the current imbalance

| Factor        | Level | Trt A                 | Trt B | Imba | lance |
|---------------|-------|-----------------------|-------|------|-------|
| Site          | 1     | 5                     | 5     | Α    | В     |
|               | 2     | 11                    | 10    | 2    | 0     |
|               | 3     | 9                     | 9     |      |       |
| Gender        | M     | 13                    | 11    | 3    | 1     |
|               | F     | 12                    | 13    |      |       |
|               | 1     | 5                     | 4     |      |       |
| Symptom Score | 2     | 13                    | 15    | 1    | 3     |
|               | >=3   | 7                     | 5     |      |       |
| Study         | All   | 25                    | 24    | 2    | 0     |
|               |       | Total Imbalances A, B |       | 8    | 4     |

**Step 4. Determine Treatment Assignment Probabilities** 

(Assign B with p=0.80; Assign A with p=0.20)

|                                  | Treatment Assignment Probabilities                          |                   |  |  |
|----------------------------------|---|-------------------|--|--|
|                                  | [associated random number range to be utilized by the IXRS] |                   |  |  |
|                                  | Trt A   | Trt B             |  |  |
| Minimum Imbalance: 1 arm         |   |                   |  |  |
| Min. Imbalance = Trt A           | p= 0.80   | p= 0.20           |  |  |
|                                  | [0.00001-0.80000]   | [0.80001-0.99999] |  |  |
| Min. Inches on Tat D             | p= 0.20   | p= 0.80           |  |  |
| Min. Imbalance = Trt B           | [0.80001-0.99999]   | [0.00001-0.80000] |  |  |
| Minimum Imbalance: 2 arms        |   |                   |  |  |
| Min Inch along St. Tot A. Tot D. | p= 0.50 Sign  | p= 0.50           |  |  |
| Min. Imbalance = Trt A, Trt B    | p= 0.50 (0.0000) (0.00001-0.50000)                          | [0.50001-0.99999] |  |  |

#### Step 5. Assign next available Random Number

Compare Assigned Rand\_No against the Step 4 Probabilities

Almac CT Biostats

#### **Assign Treatment:**

Almac CT Biostats

- 0.00001<= Rand\_No <= 0.80000: assign Treatment B</li>
- 0.80001<= Rand\_No <= 0.99999: assign **Treatment A**

TrialID,Seq\_NO,Rand\_NO Protocol,1001,0.73902 Protocol,1002,0.27248

Protocol, 1003, 0.70953

Protocol, 1004, 0.31916

Protocol, 1005, 0.36785

Protocol, 1006, 0.10449

Protocol, 1007, 0.03680

Protocol, 1008, 0.53333

Protocol, 1009, 0.37130

Protocol, 1010, 0.04019

Protocol.1011.0.79345

Protocol, 1012, 0.95910

Protocol, 1013, 0.64804

Protocol, 1014, 0.33911

Protocol, 1015, 0.33736

Protocol, 1016, 0.37804

Protocol, 1017, 0.56103

Protocol, 1018, 0.95252

Protocol, 1019, 0.48285

Protocol, 1020, 0.71221

## **CAR Key Highlights**

- Almac conducts preliminary sims to provide statistical justification and help determine parameters
- Separate Almac document (from IXRS requirements document(s)):
  - CARURS: Covariate Adaptive Randomization User Requirements Specification
  - CARURS Approvers (only person(s) permitted to know details of CAR algorithm)
- Random Numbers List (for probabilistic treatment arm assignment)
- Handling of Special Cases (mis-stratification; randomized in error; site transfers)
- CAR Validation Process
- Extended timelines for Development and Testing of the adaptive randomization algorithm
- Potential need to plan for re-randomization tests to check for Type I Error at the end of study

Questions?

Almac CT Biostats

Almac Cr Biostals

Almac CT Biostats

Almac CT Biostats